Streptococcus bovis Bacteremia Management
In a patient with Streptococcus bovis bacteremia and no valvular abnormalities on echocardiogram, treat with penicillin or ceftriaxone for 2-4 weeks based on penicillin susceptibility, and perform colonoscopy to screen for colorectal malignancy.
Antibiotic Regimen
For Penicillin-Susceptible S. bovis (MIC ≤0.12 μg/mL)
The treatment approach depends on whether this represents uncomplicated bacteremia versus occult endocarditis:
Standard 4-week regimen (preferred for most cases):
- Penicillin G 12-18 million units IV daily in divided doses, OR
- Ceftriaxone 2g IV/IM once daily
- Expected cure rate >98% 1, 2
Shortened 2-week regimen (for uncomplicated cases):
- Penicillin G or ceftriaxone (same doses as above) PLUS
- Gentamicin 3 mg/kg IV/IM once daily
- This combination achieves synergistic killing and allows shorter duration 1, 2
Important caveat: The 2-week regimen should only be used in truly uncomplicated cases without evidence of endocarditis, metastatic infection, or immunocompromise. Given that echocardiography can miss vegetations (especially with transthoracic echo), and S. bovis has high endocarditis potential, the 4-week regimen is safer when any uncertainty exists 2.
For Penicillin-Allergic Patients
- Vancomycin 15 mg/kg IV every 12 hours (adjust for renal function) 2
Colonoscopy Requirement
Yes, colonoscopy is mandatory. Both major guidelines explicitly state that patients with S. bovis (now reclassified as Streptococcus gallolyticus) bacteremia or endocarditis should undergo colonoscopy to evaluate for colorectal malignancy or adenomatous polyps 1.
Evidence Supporting Colonoscopy:
The association between S. bovis and colonic pathology is well-established:
- Studies show 47-77% of patients with S. bovis bacteremia have colonic lesions (adenomas or carcinomas) when colonoscopy is performed 3, 4
- This association exists even without endocarditis 5, 3
- The subspecies matters: S. gallolyticus subsp. gallolyticus has the strongest association with colon cancer (33% endocarditis rate), but even other subspecies warrant evaluation 6, 7
Timing: Colonoscopy should be performed once the patient is clinically stable and bacteremia is controlled, typically after initiating appropriate antibiotics.
Critical Diagnostic Considerations
Echocardiography Limitations
Even though the initial echo showed no valvular abnormalities, remain vigilant:
- Consider transesophageal echocardiography (TEE) if transthoracic echo (TTE) was performed, as TTE can miss vegetations
- S. gallolyticus subsp. gallolyticus carries a 33% risk of endocarditis 6
- Monitor for persistent bacteremia (positive blood cultures 48-72 hours after starting antibiotics), which suggests endocarditis 2
- Repeat echocardiography if clinical deterioration occurs or new murmur develops
Subspecies Identification
If available, request subspecies identification of the S. bovis isolate:
- S. gallolyticus subsp. gallolyticus: Highest endocarditis risk (33%), strongest colon cancer association 6
- S. infantarius subsp. infantarius: Moderate endocarditis risk (16%) 6
- S. gallolyticus subsp. pasteurianus and S. lutetiensis: Lower endocarditis risk (5% each), but still require colonoscopy 6, 7
Monitoring During Treatment
- Obtain blood cultures every 24-48 hours until clearance is documented 1
- Count treatment duration from the first day of negative blood cultures, not from the day antibiotics started 1, 2
- Monitor for complications: embolic events, heart failure, new murmurs
- Check renal function if using gentamicin; monitor gentamicin levels if treatment exceeds 3-5 days
Common Pitfalls to Avoid
- Don't skip colonoscopy even with negative echo—the colon cancer association exists independent of endocarditis
- Don't use the 2-week regimen if there's any uncertainty about endocarditis or if patient has prosthetic material
- Don't assume TTE rules out endocarditis—TEE is more sensitive for vegetations
- Don't forget to check for polymicrobial bacteremia—16% of S. bovis cases have concurrent gram-negative bacteremia, particularly E. coli 3
- Don't overlook hepatobiliary sources—13% present with cholecystitis or biliary tract infection 3